London, 11 Dec 2025: A major European clinical study, EASEE4YOU, is preparing to launch in the UK, with Great Ormond Street Hospital (GOSH) joining the international research effort. The study will investigate an emerging neurostimulation therapy designed for adolescents living with drug-resistant focal epilepsy.
EASEE4YOU is assessing a minimally invasive brain-stimulation system intended for young people whose seizures have not improved after trying at least two anti-seizure medications. The EASEE System has previously received CE approval for adult use, but this marks the first structured evaluation of the technology in adolescents aged 12 to 17.
Drug-resistant focal epilepsy can be debilitating for young patients, often limiting daily life and placing significant strain on families. By generating clinical data in adolescents, the EASEE4YOU study aims to support regulatory approval for this age group and potentially introduce a new treatment option for those who have few alternatives left.
A statement published by Health Tech Digital features remarks from Mr. Martin Tisdall, Consultant Paediatric Neurosurgeon at Great Ormond Street Hospital (GOSH). He noted:
“We’re pleased to be joining this research programme, as at Great Ormond Street Hospital we see first-hand the impact treatment-resistant epilepsy has on young people and their families. Taking part in EASEE4YOU allows us to explore a gentle, minimally invasive treatment option, and we hope this research will pave the way for safer, more effective solutions that improve quality of life for these young people.”
The EASEE device delivers continuous, targeted electrical pulses to influence brain activity linked to seizures. Unlike deep brain stimulation, which requires more invasive surgery, this system uses a thin electrode placed under the scalp connected to a pulse generator implanted in the chest. The aim is to provide sustained stimulation that helps lower seizure frequency over time. More than 150 adult patients across several European countries, including the UK, have already received the implant, signalling a growing acceptance of the technology among clinicians.
The study itself is a single-arm, prospective, interventional and multicentre trial, following 35 adolescents across sites in Germany, Austria and the UK. After a two-month monitoring period, participants undergo implantation, with the device switched on one month later. They will be followed for up to three years, with the key measure being how many patients achieve at least a 50% reduction in seizure frequency after six months of active stimulation.
The launch of EASEE4YOU in the UK represents a significant step toward expanding treatment pathways for adolescents with severe epilepsy. With GOSH joining the research programme and evidence already emerging from adult patients, the study aims to build the clinical foundation needed for broader approval. Initial findings are expected in 2027, which may offer the first indication of how effective this therapy could be for young people with drug-resistant focal epilepsy.
